

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Abert Boeckh
Serial No. : 10/783,459
For : Topical Formulations Comprising 1-N-Arylpyrazole
Derivatives and Amitraz
Filed : February 20, 2004
Examiner : LEVY, NEIL S
Group Art Unit : 1615
Confirmation No. : 7475

3239 Satellite Blvd., Duluth, Georgia 30096-4640
745 Fifth Avenue, New York, New York 10151

Filed via EFS-WEB
On April 23, 2008

**AMENDMENT AND RESPONSE TO OFFICE ACTION
UNDER 37 C.F.R. § 1.111, RECORD OF INTERVIEW AND REQUEST FOR INTERVIEW**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This is in response to the Office Action mailed January 28, 2008, setting a three month term for reply. The Commissioner is hereby authorized to charge any required fee for this paper, or credit any overpayment in fees for this paper, to Deposit Account No. 50-0320.

Amendments to the claims begin on page 3 of this paper.

Remarks begin on page 14 of this paper.

RECORD OF INTERVIEW

This is to record matters discussed during the January 9, 2008 telephonic interview among Examiner Neil S. Levy (Primary Examiner) and Applicant's representative Howard C. Lee (Patent Agent, Reg. No. 48,104). Examiner Levy is thanked for the many courtesies extended during the interview.

Claims 1-12 were discussed with regard to the restriction issued in the last Office Action. Howard Lee specified that n in formula 1, shown in claim 12 was elected to be 1 and R₁₃ was elected to be CF₃. The Examiner confirmed that Group I formulations of formula 1 with CF₃ as R₁₃ and n as 1, otherwise as indicated in the response to restriction of November 12, 2007 would be examined.

Accordingly, a summary and record of the interview is provided herewith.